<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592706</url>
  </required_header>
  <id_info>
    <org_study_id>IVY02</org_study_id>
    <nct_id>NCT03592706</nct_id>
    <nct_alias>NCT01024530</nct_alias>
  </id_info>
  <brief_title>Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy</brief_title>
  <official_title>A Phase II/III Clinical Trial With Ex Vivo Expanded Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivy Life Sciences, Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ivy Life Sciences, Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune
      killer cells in treating hepatocellular carcinoma patients in：

        1. Reduction of tumor size

        2. Reducing the relapse rate: Reducing the frequency of TACE treatment by IKC injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II/III clinical study. Blood is drawn from the patient and brought to our
      laboratory for isolation of immune cells. These immune cells are then proliferated over a two
      week period and used to produce the patented product IKC (Immune Killer Cells). The IKC will
      then infused back into the patient to treat the cancer. Each patient will receive a total of
      twelve infusions.

      60 patients are anticipated to be recruited. This is a double-arm study, the experimental
      group will receive IKC treatment along with TACE treatment. The control group will receive
      only TACE treatment. 30 patients will be randomized into each arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2009</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of tumor size</measure>
    <time_frame>One year</time_frame>
    <description>Evaluate the efficacy of autologous immune killer cells using Response Evaluation Criteria in Solid Tumors (RECIST) by recording net changes of tumor sizes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>One year</time_frame>
    <description>The length of time during and after the treatment of a disease, that a patient lives with the disease but it does not get worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of immune responses</measure>
    <time_frame>One year</time_frame>
    <description>Evaluate the efficacy and safety of in vitro proliferating autoimmune killer cells as adjuvant therapy for the treatment of liver cancer patients and promote anti-cancer immune responses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HepatoCellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>IKC and TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TACE (Transcatheter Arterial Chemoembolization)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IKC (Immune Killer Cells)</intervention_name>
    <arm_group_label>IKC and TACE</arm_group_label>
    <other_name>Autologous Immune Killer Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE (Transcatheter Arterial Chemoembolization)</intervention_name>
    <arm_group_label>IKC and TACE</arm_group_label>
    <arm_group_label>TACE</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign and give written informed consent.

          2. Age≧20 years, but＜80 years.

          3. Hepatocellular carcinoma by CT, MRI, AFP, angiography or cytology/biopsy examinations.

          4. Barcelona staging system stage B and C.

          5. Never receive TACE treatment and comply with the standard of TACE treatment.

          6. Child-Pugh stage A and B.

          7. ECOG performance status 0 to 2.

        Exclusion Criteria:

          1. Participant of other clinical trial within the past 4 weeks of screening period.

          2. Receiver of chemotherapy, radiotherapy, immunotherapy, hormone therapy, local tumor
             therapy, or target therapy within the past 4 weeks of screening period.

          3. Carriers of HIV or HTLV within the past 4 weeks of screening period.

          4. With Active acute or chronic infection by (investigator's judgement).

          5. Other diseases, except hepatocellular carcinoma, which are life-threatening to the
             patients (by investigator's judgement) for example:

             5.1 Active cardiac disease requiring therapy for coronary artery disease, congestive
             heart failure, arrhythmia or myocardial infarction.

             5.2 With previous history of encephalopathy within the past six months.

             5.3 Involved Involving systemically or known central nerve system diseases(brain or
             meningeal metastasis).

          6. Women of pregnant or breast-feeding or child-bearing potential but without adequate
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung-Bao Hsieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Executive Assistant</last_name>
    <phone>(02)8981-3333</phone>
    <phone_ext>114</phone_ext>
    <email>thesteve@ivy-cd56.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tri Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Bao Hsieh, MD</last_name>
      <phone>02-87923311</phone>
      <phone_ext>17245</phone_ext>
      <email>albert0920@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chung-Bao Hsieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HepatoCellular Carcinoma</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Immune Killer Cells</keyword>
  <keyword>IKC</keyword>
  <keyword>Immune Therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>IVY</keyword>
  <keyword>IVY02</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

